Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 8,247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 29, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

NCT01394211
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Tissue Oxygenation Measurement Using Multimodal Devices

NCT05784103
View directory record Official record
Conditions
Oxygen Saturation
Interventions
Clarifi Modulum, Perimed PeriFlux 5000, Apple Watch Oxygen Sensor, Innovo iP 900AP
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

NCT02297542
View directory record Official record
Conditions
Elderly Immune System
Interventions
Flu Vaccine
Biological
Lead sponsor
Health Sciences North Research Institute
Other
Eligibility
20 Years and older
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

NCT02768805
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Endwell, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 29, 2026, 6:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle

NCT01644279
View directory record Official record
Conditions
Sarcopenia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
20 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change

NCT03304262
View directory record Official record
Conditions
Healthy
Interventions
rTMS
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Results available

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

NCT01464827
View directory record Official record
Conditions
Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
Interventions
ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
60
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers

NCT01483469
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, RO5011232
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

NCT01776541
View directory record Official record
Conditions
Pandemic H5N1 Influenza
Interventions
Adjuvanted H5N1 pandemic influenza vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 64 Years
Enrollment
979 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

NCT01990846
View directory record Official record
Conditions
Influenza
Interventions
Flufirvitide 3, Placebo for Flufirvitide-3
Drug
Lead sponsor
Autoimmune Technologies, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 29, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

NCT02264288
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot
Interventions
PDA-002, Placebo
Biological · Other
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 29, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

NCT00524173
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir & Emtricitabine, Tenofovir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 29, 2026, 6:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

NCT04844073
View directory record Official record
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
Interventions
TAK-186
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Results available

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

NCT00552396
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Anti-KIR (1-7F9)
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Indianapolis, Indiana • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 29, 2026, 6:06 AM EDT
Completed No phase listed Observational Results available

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

NCT01364896
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions
Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 29, 2026, 6:06 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT07706686
View directory record Official record
Conditions
Healthy Volunteers, Dengue, Human Challenge Trial
Interventions
rDEN2delta30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 29, 2026, 6:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

NCT02734290
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, Paclitaxel, Capecitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 6:06 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

NCT05677360
View directory record Official record
Conditions
Human Papilloma Virus (HPV) Vaccine
Interventions
HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 29, 2026, 6:06 AM EDT
Not listed Not applicable Interventional

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

NCT06600724
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 6:06 AM EDT